Imagion Biosystems, Inc

At Imagion Biosystems (ASX:IBX), we’re on a mission to improve how cancer is detected—safely, accurately, and without radiation. ? In the latest Health Kick Podcast, our Executive Chair, Bob Proulx, joins Stockhead’s biotech expert, tim boreham, to discuss our breakthrough approach to cancer imaging.? ? Our nanoparticle-based technology is designed to provide a safer, more precise alternative to current methods, addressing critical medical needs and reducing unnecessary procedures. ? As we move forward with our Phase 2 clinical studies and an Investigational New Drug (IND) application with the FDA, we invite you to learn more about how we’re advancing the future of cancer detection. ???Listen to the full episode here:?https://lnkd.in/ghP2xuz2 #biotech #healthtech #cancerimaging #medicalinnovation #ImagionBiosystems #HealthKickPodcast

We're making exciting progress in the next phase of our breakthrough technology for non-invasive cancer detection. In this interview with Fraser Palamara of?Stockhead, our CEO, Bob Proulx, shares key updates on our journey, what’s next, and how we’re shaping the future of cancer diagnostics. ???Watch the full interview here:?https://lnkd.in/gi9_bfP5 #CancerDetection #ImagionBiosystems #Biotech #MedicalInnovation #Diagnostics #HealthcareTech #MagSense

We’re honored to be featured in Stockhead’s latest article, highlighting Imagion Biosystems as one of the ASX-listed cancer-fighting stocks with strong investment potential. ? At Imagion, we are dedicated to making molecular-based imaging a reality and changing the way cancer is detected.?Our non-radioactive imaging technology works with existing MRI scanners and gives radiologists a new way to see cancer. We are driven to improve patient outcomes by achieving earlier and better detection of cancer. ? With imaging agents for breast cancer, prostate cancer, and ovarian cancer in development, we are excited about what’s ahead. ??? Check out the article to learn more about why Imagion Biosystems: https://lnkd.in/gazM7yGF #CancerResearch #Biotech #InvestmentOpportunities #MagSense #ImagionBiosystems #CancerDiagnostics #ASXStocks

???Exciting news from Imagion Biosystems! We’ve initiated manufacturing of the MagSense? HER2 Imaging Agent, a key step toward our Phase 2 clinical study and FDA IND filing in mid-2025. This milestone moves us closer to delivering a more precise, non-invasive imaging solution for the 400,000+ HER2+ breast cancer patients diagnosed annually. Grateful for our team’s dedication as we advance toward the next phase! Read the full announcement: https://lnkd.in/gTzexxbH #ImagionBiosystems #MagSense #BreastCancer #OncologyInnovation #MedicalImaging #Biotech #CancerDetection

??? We appreciate Stockhead for highlighting the important work Imagion Biosystems, Inc and other ASX biotechs are doing to advance early cancer detection. It’s great to see recognition for the innovative technologies shaping the future of healthcare. Proud to be part of this mission! ???? Read the full article in The Australian here: ?? https://lnkd.in/g38e2psM #MagSense #EarlyCancerDetection

Imagion Biosystems, Inc. is thrilled to join global healthcare leaders, fast-growing innovators, and the investment community at the 43rd Annual J.P. Morgan Healthcare Conference this week in San Francisco. Our CEO, Bob Proulx, will be sharing how our MagSense? molecular MRI platform is transforming cancer detection. Attending #JPM2025? Let’s connect and discuss the future of healthcare innovation! #MagSense #HealthcareInnovation

We are grateful to continue our mission, one we are so passionate about, to revolutionize cancer detection and treatment. At our recent EGM, Imagion Biosystems, Inc shareholders approved a $3M capital raise to support our IND filing — an essential step toward advancing our #MagSense imaging agent technology. We sincerely thank our shareholders for their trust and continued support! For more details about the EGM results, read our full announcement: https://lnkd.in/gXunE5GM. #ImagionBiosystems #EGM #IND #CancerDetection #ShareholderSupport #BiotechNews $IBX

Imagion Biosystems is featured in a Special Report?by Stockhead?for our continuous work on the MagSense? nanoparticles! Our innovative molecular imaging technology aims to transform cancer diagnosis by bringing molecular MRI to life. The article highlights: ??? Our focus on HER2+ breast cancer staging, with future pipeline candidates targeting prostate and ovarian cancers ?? How the recent $3M capital raise is driving the next phase of development and commercialization ?? The potential impact of MagSense? to revolutionize early cancer detection and improve outcomes We’re thrilled about the progress we’ve made and excited for what’s ahead in advancing cancer detection through cutting-edge technology. ???Read the full article and join us on this journey to transform healthcare: https://lnkd.in/gd4zHx2P #CancerDetection #MRI #MagSense #ImagionBiosystems #InnovationInHealthcare #Biotech $IBX

We’re in Chicago this week, attending #RSNA24 from Dec. 2-4! ?? Join us and imaging professionals from around the world to discover innovations like #MagSense that are driving healthcare forward. Let us know if you’ll be there, we’d love to connect! ?? ?? Learn more about the meeting:?https://lnkd.in/d7b2bB5 #Radiology #HealthcareInnovation #RSNA

We appreciate the recognition by The Market Bull - Daily Stock News and are grateful for the support in the Australian capital markets.